Top Industry Leaders in the Next Generation Sequencing Market
Latest Next Generation Sequencing Companies Updates:
S2 Genomics: Raised $16 million in Series A funding to accelerate the commercial adoption of their single-cell or -nuclei sample preparation platform for solid tissues.
Caris Life Sciences (NASDAQ: CAR): Initiated a Phase 2 clinical trial evaluating their Precision Oncology 9 Genomic Sequencing Assay in conjunction with their Caris Precision Medicine Therapy™ for advanced head and neck cancer patients.
Illumina (ILMN): Launched a Phase 2 study evaluating their NGS-based liquid biopsy assay for detecting minimal residual disease in early-stage breast cancer patients after neoadjuvant therapy.
Thermo Fisher Scientific (TMO): Acquired PacBio, a leading developer of single-molecule sequencing technology, expanding their NGS portfolio and offering improved long-read sequencing capabilities.
Illumina: Partnered with BioMarin Pharmaceutical (BMRN) to develop and commercialize NGS-based companion diagnostics for BioMarin's gene therapy treatments.Agilent Technologies (A): Entered into a collaboration with Guardant Health (GH) to combine their respective strengths in NGS and liquid biopsy technologies for early cancer detection and monitoring.
List of Next Generation Sequencing companies in the market:
-
Becton Eurofins Scientific (US)
-
Illumina, Inc. (US)
-
Genome Life Sciences (India)
-
GenScript (US)
-
Thermo Fisher Scientific, Inc. (US)
-
Qiagen (Germany)
-
PerkinElmer, Inc. (US)
-
F. Hoffmann-La Roche Ltd (Switzerland)
-
Pacific Biosciences of California, Inc. (US)
